NCT04091386Completed
Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
Observational Study Evaluating the Physical Activity in a Subset of Damoctocog Alfa Pegol Treated Hemophilia A Patients Who Are Enrolled in the HEM-POWR Study.
Source: ClinicalTrials.gov · Last updated 15 Jun 2025
Brief summary (registry, in English)
In this study researcher want to learn more about the change of physical activity of hemophilia A patients treated with damoctocog alfa pegol. Patients enrolled in this study will be wearing a small device measuring daily active time. Researcher will compare these physical activity data with patient's clinical data including bleeding events to gain information on how bleeding levels are related to the activity level of the patients. The study aims to enroll about 80 patients who are at the same time also participating in the HEM-POWR study (NCT03932201) evaluating the effectiveness and safety of damoctocog alfa pegol.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 10 (actual)
- First submitted
- 30 Aug 2019
- Start date
- 10 Jun 2021
- Primary completion date
- 7 May 2024
- Lead sponsor
- Bayer
- Diseases
- Haemophilia
- NCT number
- NCT04091386
What you commit to
- Study type: Observational
- Participants enrolled: 10
- From 10 Jun 2021 to the primary completion date, 7 May 2024
- 8 sites in 7 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hypersensitivity to any material of activity monitor (e.g. steel, rubber)
Other
- Time gap between enrollment to HEM-POWR study and enrollment to LIFE-ACTIVE study is greater than 6 months
Who the study is looking for
- Enrolled in the HEM-POWR study (NCT03932201)
- Naïve to damoctocog alfa pegol prior to enrollment to HEM-POWR study
- Prescribed for prophylaxis treatment for hemophilia with damoctocog alfa pegol
- Patient is willing to wear the provided device
- Signed informed consent/assent to participate in LIFE-ACTIVE: Observational study evaluating the physical activity in a subset of damoctocog alfa pegol treated Hemophilia A patients who are enrolled in the HEM-POWR study
Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Belgium | Unknown status |
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Canada | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Spain | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Italy | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Slovenia | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Taiwan | Unknown status |
| Tulane University Coordinator of this site? Confirm its status | New Orleans | United States | Unknown status |
| Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders Coordinator of this site? Confirm its status | Orange | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.